A citation-based method for searching scientific literature

Jeppe Sturis, Carsten F Gotfredsen, John Rømer, Bidda Rolin, Ulla Ribel, Christian L Brand, Michael Wilken, Karsten Wassermann, Carolyn F Deacon, Richard D Carr, Lotte Bjerre Knudsen. Br J Pharmacol 2003
Times Cited: 159







List of co-cited articles
922 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
32

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
Bidda Rolin, Marianne O Larsen, Carsten F Gotfredsen, Carolyn F Deacon, Richard D Carr, Michael Wilken, Lotte Bjerre Knudsen. Am J Physiol Endocrinol Metab 2002
237
31

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode. Lancet 2009
769
26



Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Bernard Zinman, John Gerich, John B Buse, Andrew Lewin, Sherwyn Schwartz, Philip Raskin, Paula M Hale, Milan Zdravkovic, Lawrence Blonde. Diabetes Care 2009
621
22

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
788
21


Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.
L B Knudsen, P F Nielsen, P O Huusfeldt, N L Johansen, K Madsen, F Z Pedersen, H Thøgersen, M Wilken, H Agersø. J Med Chem 2000
450
19

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
722
18

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.
Søren Bregenholt, Annette Møldrup, Niels Blume, Allan E Karlsen, Birgitte Nissen Friedrichsen, Ditte Tornhave, Lotte Bjerre Knudsen, Jacob S Petersen. Biochem Biophys Res Commun 2005
142
18

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Richard E Pratley, Michael Nauck, Timothy Bailey, Eduard Montanya, Robert Cuddihy, Sebastiano Filetti, Anne Bloch Thomsen, Rie Elvang Søndergaard, Melanie Davies. Lancet 2010
428
18

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
T Vilsbøll, B Brock, H Perrild, K Levin, H-H Lervang, K Kølendorf, T Krarup, O Schmitz, M Zdravkovic, T Le-Thi,[...]. Diabet Med 2008
160
17

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
17


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
944
17

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
876
17

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
16

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Kristine B Degn, Claus B Juhl, Jeppe Sturis, Grethe Jakobsen, Birgitte Brock, Visvanathan Chandramouli, Joergen Rungby, Bernard R Landau, Ole Schmitz. Diabetes 2004
331
16

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
Loredana Farilla, Angela Bulotta, Boaz Hirshberg, Sergio Li Calzi, Nasif Khoury, Houtan Noushmehr, Cristina Bertolotto, Umberto Di Mario, David M Harlan, Riccardo Perfetti. Endocrinology 2003
474
15



The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
15


Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Alexandra E Butler, Juliette Janson, Susan Bonner-Weir, Robert Ritzel, Robert A Rizza, Peter C Butler. Diabetes 2003
14

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.
Loredana Farilla, Hongxiang Hui, Cristina Bertolotto, Elizabeth Kang, Angela Bulotta, Umberto Di Mario, Riccardo Perfetti. Endocrinology 2002
381
14

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
Lotte Bjerre Knudsen, Lars Wichmann Madsen, Søren Andersen, Kasper Almholt, Anne S de Boer, Daniel J Drucker, Carsten Gotfredsen, Frederikke Lihme Egerod, Anne Charlotte Hegelund, Helene Jacobsen,[...]. Endocrinology 2010
342
14

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
903
13

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
Annette M Chang, Grethe Jakobsen, Jeppe Sturis, Marla J Smith, Cathie J Bloem, Bob An, Andrzej Galecki, Jeffrey B Halter. Diabetes 2003
168
13

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
928
13

Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight.
Bronislava R Gedulin, Svetlana E Nikoulina, Pamela A Smith, George Gedulin, Loretta L Nielsen, Alain D Baron, David G Parkes, Andrew A Young. Endocrinology 2005
191
13

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
395
13


The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.
Niels Vrang, Jacob Jelsing, Lotte Simonsen, Andres Eskjær Jensen, Inger Thorup, Henrik Søeborg, Lotte Bjerre Knudsen. Am J Physiol Endocrinol Metab 2012
65
20

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
John B Buse, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Cheng-Tao Chang, Yizhen Xu, Lawrence Blonde, Julio Rosenstock. Diabetes Care 2010
140
12



One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Mathijs C Bunck, Michaela Diamant, Anja Cornér, Bjorn Eliasson, Jaret L Malloy, Rimma M Shaginian, Wei Deng, David M Kendall, Marja-Riitta Taskinen, Ulf Smith,[...]. Diabetes Care 2009
303
11

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
David C Klonoff, John B Buse, Loretta L Nielsen, Xuesong Guan, Christopher L Bowlus, John H Holcombe, Matthew E Wintle, David G Maggs. Curr Med Res Opin 2008
551
11





The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
11


Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Arne Astrup, Stephan Rössner, Luc Van Gaal, Aila Rissanen, Leo Niskanen, Mazin Al Hakim, Jesper Madsen, Mads F Rasmussen, Michael E J Lean. Lancet 2009
621
11


The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Bernard Zinman, Byron J Hoogwerf, Santiago Durán García, Denái R Milton, Joseph M Giaconia, Dennis D Kim, Michael E Trautmann, Robert G Brodows. Ann Intern Med 2007
345
10


Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Steven E Kahn, Steven M Haffner, Mark A Heise, William H Herman, Rury R Holman, Nigel P Jones, Barbara G Kravitz, John M Lachin, M Colleen O'Neill, Bernard Zinman,[...]. N Engl J Med 2006
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.